全文获取类型
收费全文 | 3557370篇 |
免费 | 269244篇 |
国内免费 | 8662篇 |
专业分类
耳鼻咽喉 | 48953篇 |
儿科学 | 118329篇 |
妇产科学 | 99844篇 |
基础医学 | 499865篇 |
口腔科学 | 102154篇 |
临床医学 | 323616篇 |
内科学 | 691447篇 |
皮肤病学 | 82601篇 |
神经病学 | 291875篇 |
特种医学 | 139421篇 |
外国民族医学 | 1130篇 |
外科学 | 534878篇 |
综合类 | 79186篇 |
现状与发展 | 6篇 |
一般理论 | 1403篇 |
预防医学 | 276962篇 |
眼科学 | 81493篇 |
药学 | 264601篇 |
9篇 | |
中国医学 | 6739篇 |
肿瘤学 | 190764篇 |
出版年
2018年 | 37669篇 |
2017年 | 29191篇 |
2016年 | 33569篇 |
2015年 | 38191篇 |
2014年 | 52535篇 |
2013年 | 79616篇 |
2012年 | 105891篇 |
2011年 | 111873篇 |
2010年 | 67323篇 |
2009年 | 64506篇 |
2008年 | 105333篇 |
2007年 | 111636篇 |
2006年 | 113481篇 |
2005年 | 109335篇 |
2004年 | 106157篇 |
2003年 | 102078篇 |
2002年 | 98802篇 |
2001年 | 167192篇 |
2000年 | 171681篇 |
1999年 | 144688篇 |
1998年 | 39753篇 |
1997年 | 35231篇 |
1996年 | 35145篇 |
1995年 | 36332篇 |
1994年 | 33601篇 |
1993年 | 31581篇 |
1992年 | 115920篇 |
1991年 | 112623篇 |
1990年 | 109316篇 |
1989年 | 105889篇 |
1988年 | 97618篇 |
1987年 | 95937篇 |
1986年 | 90733篇 |
1985年 | 86997篇 |
1984年 | 65079篇 |
1983年 | 55569篇 |
1982年 | 32860篇 |
1981年 | 29526篇 |
1979年 | 59619篇 |
1978年 | 41779篇 |
1977年 | 35430篇 |
1976年 | 33078篇 |
1975年 | 35269篇 |
1974年 | 42295篇 |
1973年 | 40342篇 |
1972年 | 37728篇 |
1971年 | 35241篇 |
1970年 | 32447篇 |
1969年 | 31039篇 |
1968年 | 28391篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Anna Ugalde BA PhD Victoria White BA MA PhD Nicole M. Rankin BA MSc PhD Christine Paul BA PhD Catherine Segan BA PhD Sanchia Aranda RN BAppSci MN PhD Anna Wong Shee BSc BAppSc PhD Alison M. Hutchinson RN BApp Sci MBioth PhD Patricia M. Livingston BA PhD 《CA: a cancer journal for clinicians》2022,72(3):266-286
Smoking cessation reduces the risk of death, improves recovery, and reduces the risk of hospital readmission. Evidence and policy support hospital admission as an ideal time to deliver smoking-cessation interventions. However, this is not well implemented in practice. In this systematic review, the authors summarize the literature on smoking-cessation implementation strategies and evaluate their success to guide the implementation of best-practice smoking interventions into hospital settings. The CINAHL Complete, Embase, MEDLINE Complete, and PsycInfo databases were searched using terms associated with the following topics: smoking cessation, hospitals, and implementation. In total, 14,287 original records were identified and screened, resulting in 63 eligible articles from 56 studies. Data were extracted on the study characteristics, implementation strategies, and implementation outcomes. Implementation outcomes were guided by Proctor and colleagues' framework and included acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, and sustainability. The findings demonstrate that studies predominantly focused on the training of staff to achieve implementation. Brief implementation approaches using a small number of implementation strategies were less successful and poorly sustained compared with well resourced and multicomponent approaches. Although brief implementation approaches may be viewed as advantageous because they are less resource-intensive, their capacity to change practice in a sustained way lacks evidence. Attempts to change clinician behavior or introduce new models of care are challenging in a short time frame, and implementation efforts should be designed for long-term success. There is a need to embrace strategic, well planned implementation approaches to embed smoking-cessation interventions into hospitals and to reap and sustain the benefits for people who smoke. 相似文献
12.
Kinase alterations are increasingly recognised as oncogenic drivers in mesenchymal tumours. Infantile fibrosarcoma and the related renal tumour, congenital mesoblastic nephroma, were among the first solid tumours shown to harbour recurrent tyrosine kinase fusions, with the canonical ETV6::NTRK3 fusion identified more than 20 years ago. Although targeted testing has long been used in diagnosis, the advent of more robust sequencing techniques has driven the discovery of kinase alterations in an array of mesenchymal tumours. As our ability to identify these genetic alterations has improved, as has our recognition and understanding of the tumours that harbour these alterations. Specifically, this study will focus upon mesenchymal tumours harbouring NTRK or other kinase alterations, including tumours with an infantile fibrosarcoma-like appearance, spindle cell tumours resembling lipofibromatosis or peripheral nerve sheath tumours and those occurring in adults with a fibrosarcoma-like appearance. As publications describing the histology of these tumours increase so, too, do the variety kinase alterations reported, now including NTRK1/2/3, RET, MET, RAF1, BRAF, ALK, EGFR and ABL1 fusions or alterations. To date, these tumours appear locally aggressive and rarely metastatic, without a clear link between traditional features used in histological grading (e.g. mitotic activity, necrosis) and outcome. However, most of these tumours are amenable to new targeted therapies, making their recognition of both diagnostic and therapeutic import. The goal of this study is to review the clinicopathological features of tumours with NTRK and other tyrosine kinase alterations, discuss the most common differential diagnoses and provide recommendations for molecular confirmation with associated treatment implications. 相似文献
13.
Lykov A. P. Uvarov I. P. Gevorgiz R. G. Zheleznova S. N. 《Bulletin of experimental biology and medicine》2022,172(3):301-304
Bulletin of Experimental Biology and Medicine - We studied the effect of microalgae of various systematic groups added to the ration on the biochemical parameters of blood serum and liver and... 相似文献
14.
Osama Y Safdar Rana M Baghdadi Sereen A Alahmadi Bana E Fakieh Amaal M Algaydi 《World Journal of Clinical Pediatrics》2022,11(1):14-26
Whether the underlying mutations are homozygous, heterozygous, or co-inherited with other hemoglobinopathies, sickle cell disease is known to afflict the kidneys, leading to the clinical entity known as sickle cell nephropathy (SCN). Although common, SCN remains diagnostically elusive. Conventional studies performed in the context of renal disorders often fail to detect early stage SCN. This makes the quest for early diagnosis and treatment more challenging, and it increases the burden of chronic kidney disease-related morbidity among patients. Novel diagnostic tools have been employed to overcome this limitation. In this study, we discuss various biomarkers of SCN, including those employed in clinical practice and others recently identified in experimental settings, such as markers of vascular injury, endothelial dysfunction, tubulo-glomerular damage, and oxidative stress. These include kidney injury molecule-1, monocyte chemoattractant protein-1, N-acetyl-B-D-glucosaminidase, ceruloplasmin, orosomucoid, nephrin, and cation channels, among others. Furthermore, we explore the potential of novel biomarkers for refining diagnostic and therapeutic approaches and describe some obstacles that still need to be overcome. We highlight the importance of a collaborative approach to standardize the use of promising new biomarkers. Finally, we outline the limitations of conventional markers of renal damage as extensions of the pathogenic process occurring at the level of the organ and its functional subunits, with a discussion of the expected pattern of clinical and biochemical progression among patients with SCN. 相似文献
15.
16.
17.
Anne-Sophie Worm Fenger Markus Harboe Olsen Maria Louise Fabritius Christian Gunge Riberholt Kirsten Møller 《Acta anaesthesiologica Scandinavica》2023,67(2):240-247
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献18.
19.
Hassona Shahd M. Saad Entsar A. Kiwan Hala A. Hassanien Mohamed M. 《Investigational new drugs》2022,40(4):681-689
Investigational New Drugs - Although many cancer drugs are clinically approved, they still suffer from no adequate efficiency or drug resistance, or bad side effects. Therefore, developing safer... 相似文献